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CHAPTER I 
INTRODUCTION 
Abnormalities in carbohydrate and lipid metabolism are 
characteristic complications of non-insulin dependent 
dic:tbetes mellitus (NIJ?DM). Hyperglycemia, hyperinsulinemia, 
and hypercholesterolemia are among the contributing factors 
to the long term complications of the disease. Trace 
minerals are known tp participate in the metabolism of both 
carbohydrates and lipids and deficiencies of certain trace 
minerals may induce symptoms similar to those of NIDDM. 
The essentiality of chromium in animals was established 
in the 1950's when chromium was identified as the active 
component in glucose tolerance factor (Mertz et al. 1974). 
sufficient evidence to support its essentiality in humans 
resulted in the addition of chromium to the Estimated Safe 
and Adequate Daily Dietary Intake (ESADDI) of the 
Recommended Dietary Allowances since 1980 (National Research 
Council 1989). 
Manganese has been found to be essential in all animal 
species studied. Defects in carbohydrate and lipid 
metabolism are among the complications common to the 
offspring of manganese-deficient animals. Known functions 
of manganese include enzyme activation and serving as a 
1 
constituent of metalloenzymes such as pyruvate carboxylase 
(Hurley & Keen 1987). 
2 
Previous research in this laboratory involved the 
effects of low chromium and low manganese diets on rats with 
streptozotocin (STZ} induced diabetes. Four weeks post 
injection of STZ, only those animals fed adequate amounts of 
both chromium and manganese displayed normal fasting glucose 
levels. 
The purpose of this study was - to investigate the 
effects and interactions which may occur in animals fed 
diets lacking in adequate amounts of chromium and manganese. 
In order to eliminate the possible effects of trace minerals 
on the efficacy of STZ, this study used the genetically 
obese mouse. This mouse, C57BL/6J (objob) is characterized 
by obesity, hyperglycemia and hyperinsulinemia making it a 
good model to examine the effects of chromium and manganese 
depletion. 
Hypothesis 
Low and adequate levels of dietary chromium and 
manganese will have significant effects on plasma glucose, 
insulin, corticosterone, and cholesterol on glycosylated 
hemoglobin and on tissue concentrations of trace minerals in 
genetically obese mice. 
Essentiality 
CHAPTER II 
REVIEW OF LITERATURE 
Chromium 
The essentiality of chromium in animals was first 
documented by Mertz et al. {1961) in the late 1950's. 
Trivalent chromium was identified as the active agent in 
glucose tolerance factor (GTr) helping to maintain normal 
glucose removal +ates from the bloodstream. Diets 
containing low amounts o f GTF resulted in impaired glucose 
tolerance in rats. The impaired glucose tolerance was 
subsequently corrected with su~plementation by trivalent 
chromium complexes. 
Glinsmann and Mertz (1966) showed improved glucose 
tolerance in three ppt of six diabetic subjects and 
suggested that chromium was essential for optimal 
utilization of glucos~ in the human. Total parenteral 
nutrition (TPN) solutions containing no added chromium 
resulted in glucose intolerance and peripheral neuropathy. 
When the patient was subsequently supplemented with 250 ug 
chromium per d ay, these s ymptoms d i s a ppeared (Jeej eebhoy, et 
al. 1977). 
3 
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It has been suggested that essentiality .,must meet four 
criteria: the essential element must be in living matter; 
it must interact with living systems; a dietary deficiency 
must consistently and specifically reduce a biologic 
function to suboptimal; and, the reduced biologic function 
must be preventabl-e or curable bY physiologic amounts of the 
nutrient. Using these criteria, it has been suggested by 
some authors that- chromium meets some but not all standards 
of essent-iality. The lack of response to chromium 
supplementation in apparent chromium-deficient neuropathy 
and the failure of serum chromium levels to rise in response 
to chromium supplementation in one case have been cited as 
questions _ in determining essentiality (Anonymous 1988). 
Anderson et al. (1985) however, demonstrated a significant 
increase in serum chromium levels following supplementation 
reflective of chromium intake but determined that serum 
chromium concentration is not a meaningful indicator of 
chromium status. 
The exact role of GTF in the potentiation of insulin is 
as yet undefined. Further, there is no evidence for 
chromium as a component of the insulin receptor either as 
part of insulin binding or in mediating the effect of 
insulin on cells. Despite questions about its essentiality 
in humans, the inclusion of an estimated safe and adequate 
daily intake (ESADDI) for chromium in the 1980 and 1989 
editions of the Recommended Dietary Allowances (National 
Research Council 1989) supports the view of essentiality in 
humans. 
Carbohydrate Metabolism 
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Trivalent chromium was · 'identified as the active agent 
in glucose tolerance factor (GTF) by Schwarz and Mertz 
(1959). Although isolation of the compound has proved 
difficult, it is thought to contain nicotinic acid, glutamic 
acid, glycine, and a sulfur containing amino acid (Mertz et 
al. 1974, Mertz 1993, Stoecker 1990);. · This complex is 
released from storage in a body pool in response to insulin 
and it subsequently acts ·to potentiate the action of insulin 
in peripheral tissues. Chromium deficiency is thought to 
decrease the sensitivity of peripheral tissue to insulin; 
much higher levels of insulin are required to maintain 
desirable serum glucose levels at suboptimal levels of 
chromium. In vitro, glucose catabolism to carbon dioxide 
was shown to respond similarly when insulin levels were 
increased as when insulin was held constant and biologically 
active chromium was added (Anderson 1984). 
Chromium increases the effectiveness of the insulin but 
is not a substitute for insulin. Chromium functions in the 
presence of insulin; no effects of chromium supplementation 
occur in the absence of insulin (Mertz 1993). Mertz showed 
a 67% increase in glucose uptake by epididymal fat tissue in 
rats fed a GTF-deficient diet supplemented with chromium . 
(III) as compared to tissue from unsupplemented controls. 
The effect of the chromium was found to be' dependent on the 
presence of small amounts of insulin (Mertz a976) ~ In: a 
review of chromium research spanning thirty~four years in 
humans as well as in animals and in vitro, Mertz (1993) 
concludes that chromium deficiency results in insulin 
resistance which can be improved with· chromium 
supplementation. 
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Hubner et al. (1989) studied the ef,fects of chromium 
supplementation on serum insulin levels in pregnant rats and 
their offspring. Pregnant Wistar rats were supplemented for 
fifty days with 1 mg CrC13 .6H2 0 by stomach tube beginning on 
day one of gestation; control rats received the same diet 
but unsupplemented water by stomach tube. No effects of 
chromium supplementation were noted on glucose tolerance but 
significant reductions in serum insulin were observed 30 
minutes after a glucose load. Among newborn pups from the 
supplemented mother group, basal concentrations of insulin 
were significantly decreased in comparison to controls. The 
lack of effect on glucose tolerance was anticipated as the 
animals were not fed a chromium-deficient diet. The authors 
suggested that the reduced level of circulating insulin was 
due to an increased efficiency of utilization of available 
insulin in response to chromium supplementation. They 
further suggested that the amount of insulin produced by the 
whole pancreas was reduced due to a lower demand for insulin 
among the chromium treated rats. Evans et al. (1973) found 
a significantly greater uptake of glucose in epididymal 
7 
tissue of .chromium-deficient rats using insulin reacted with 
GTF from brewers yeast than the effect on the same tissue 
using native insulin. Their results suggest possible 
binding sites for GTF with certain amino groups of the 
insulin molecule. 
Other research has shown less conclusive results. 
Flatt et al. (1989) questioned the effect of trivalent 
chromium on glucose ·homeostasis. They found no difference 
in effects of chromium supplemented (1 mg Cr/kg diet) or 
chromium depletion diets (0.03 mgfkg) fed for 32 days to 
Wistar rats on food intake, body weight, glycosylated 
hemoglobin, plasma glucose or plasma insulin at 53 days of 
age. Tissue chromium likewise was not significantly 
different between the two groups except for the pancreas 
which showed a 44% decrease in chromium stores in the rats 
fed deficient diets as compared to chromium supplemented 
rats. The authors conceded that they could not rule out the 
possibility that saturation of the tissues could have 
occurred prior to the onset of the deficient diet but cited 
other studies of longer duration ·with similar effects to 
back up their conclusions. Donaldson et al. (1985} fed low 
chromium (0.06 - 0.1 mg Crfkg diet) and chromium-
supplemented (5 mgfkg), high sucrose, high cholesterol diets 
to male Sprague-Dawley rats from weanling to eighteen 
months. Rats in the low chromium group showed significantly 
higher one hour postprandial plasma glucose at four and 
eight months but the significance disappeared at twelve 
8 
months and did not reoccur at fourteen or sixteen months. 
Tissue chromium concentrations, with ·the exception of kidn~y 
tissue, did ·not differ significantly :between .the two groups. 
Berggren and Flatt (1985a) examined tissue 
concentrations of chromium of genetically diabetic and lean 
mice fed a standard diet. No significant differences were 
observed. · Further, they determined that urinary chromium 
was not an accurate indicator of tissue chromium status. 
While tissue chromium· concentrations between the two groups 
were comparable, "defective handling at the cellular level 
leading to impaired metabolism of GTF and resultant glucose 
intolerance" could not be ruled out. In a follow-up study, 
Berggren and Flatt (1985b) reported that tissue chromium 
concentrations of obese hyperglycemic mice were not 
significantly different from iean mice but that injection of 
trivalent chromium intraperitoneally (2 mgfkg body weight) 
resulted in significantly higher tissue concentrations among 
the lean mice. The authors suggest that the diabetic state 
of the obese mouse is associated with rapid excretion andfor 
an inability to utilize the trivalent chromium rather than 
an actual deficiency. The positive effects of addition of 
GTF may indicate an inability of the obese mouse to convert 
trivalent chromium to active GTF. 
Preston et al. (1976) failed to find a correlation 
between glucose tolerance, peak glucose concentrations and 
serum cholesterol between ·normal, pregnant _and lactating 
guinea pigs fed chromium supplemented or depleted- diets. 
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They did see an increase in mortality among the 
pregnant-depleted diet group and suggested that chromium may 
provide some level of protective effect against the stresses 
associated with mating and pregnancy in the guinea pig. 
Their diet was .also noted to contain less protein than 
recommended by the National Research CounciJ: 
(17% vs. 25 -30%). The authors also suggested that results 
may be reflective of variations in chromium requirements 
between species noting that guinea pig insulin exhibits 
different· properties than that of other rodents or the 
bovine. 
studies with human subjects have verified a 
relationship between chromium and carbohydrate metabolism. 
Morris et al. (1992) found a significant inverse 
relationship between postprandial plasma insulin and plasma 
chromium levels. The relationship did not occur between 
plasma chromium and plasma glucose. The decrease in plasma 
chromium could not be correlated with an increase in urinary 
chromium indicating a change in uptake or binding of 
chromium within insulin sensitive tissues. 
The effect of a low chromium diet on glucose, insulin, 
glucagon and urinary chromium losses was examined by 
Anderson et al. (1991). Subjects were divided into 
hyperglycemic (> 5.56 mmol glucosefL, and < 11.1 mmol/L at 
90 minute after a 1 gjkg body weight glucose challenge) and 
control groups. All individuals with diabetes or subjects 
with abnormal blood or urine profiles were excluded from the 
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study. Dietary intakes were controlled to maintain chromium 
in the lowest quartile of normal intake for adults. In this 
double blind study, subjects received either a supplement 
(200 ug Cr tablet (CrC13 )) or a ,placebo. Hyperglycemic 
subjects receiving chromium supplementation showed 
significant improvement in glucose tolerance, circulating 
insulin and glucagon ,when compared to controls. The authors 
suggest that diets low in chromium similar to those consumed 
by 25% of the u.s. population can lead to detrimental 
effects on glucose tolerance, circulating insulin and 
glucagon in hyperglycemic persons. A study of elderly 
Canadian women (Martinez et al. 1985) verified the results 
that chromium supplementation among those .subjects with 
moderate glucose intolerance resulted in a significant 
decrease in two hour glucose levels and an increase in 
insulin sensitivity within the same group. In a six month 
trial, subjects with hyperglycemia, insulin-dependent 
diabetes mellitus (IDDM), NIDDM, and controls were 
supplemented with 218 ug chromium as high potency yeast. 
The only statistically significant results occurred among 
the group with hyperglycemia for whom blood glucose control 
improved (Vinson & Bose 1984). Fasting blood glucose levels 
dropped significantly in some diabetic subjects given a 
chromium supplement (-600 ug) for 2-4 months (Mossop 1983). 
Glinsmann and Mertz {1966) found improved glucose tolerance 
in 50% of diabetics given trivalent chromium 
supplementation; normal glucose tolerance remained 
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unaffected. Offenbacher and Pi-Sunyer ~(1980) studied the 
effects of chromium on glucose tolerance among elderly 
subjects using brewers yeast and torula yeast. Results 
indicated that 'Chromium rich brewers yeast improved glucose 
tolerance and insulin sensit:i!vity witp no changes seen in 
the control (torula yeast) group. 
A follow-up study by Offenbacher et al. (1985) found no 
significant difference in glucose tolerance or insulin 
levels among groups supplemented with chromium chloride, 
brewers yeast or placebo. Uusiptupa et al. (1983) failed to 
find any correlation between supplemental chromium and 
glucose tolerance or serum insulin in NIDDM subjects. 
Abraham et al. (1992) found beneficial effects on blood 
glucose levels to be transitory, reverting to pretreatment 
status in longer .periods of supplementation. 
Rabinowitz et al. (1980} found an inverse correlation 
between plasma chromium and fasting plasma glucose. In a 
follow-up study, Rabinowitz et. al. (1983) found a 
significant increase in postprandial insulin release in 
NIDDM subjects following supplementation of brewers yeast. 
A study by Riales and Albrink (1981) found that 
supplementation of trivalent chromium {200 ug in 5 ml of 
water) improved insulin sensitivity in subjects displaying 
insulin resistance but normal glucose tolerance. 
A study was conducted by Anderson et al. (1987) to 
examine possible effects of chromium supplementation in 
patients with reactive hypoglycemia. Eight female patients 
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with previously diagnosed .hypoglycemia were ;randomly 
assigned to either a supplemented group receiving 200 ug 
chromium as chromium chloride or a placebo in a double-blind 
crossover design. Each test period lasted twelve weeks with 
testing at six and twelve weeks during each period. 
Following a glucose load, blood samples were obtained at 30, 
60, 90, 120, 180, . 240, and 300 minutes; ·urine samples were 
obtained at. ~120 and 300 minutes. Sig-nificant results 
included a decrease in hypoglycemic area (defined as the 
area of the glucose tolerance curve which ·falls below 
fasting levels), an increase in insulin binding to red blood 
cells, an increase in number of insulin receptors and a 
reduction in hypoglycemic symptoms. Control subjects with 
normal glucose tolerance showed no change in glucose 
tolerance, receptor number, or receptor affinity but did 
show increases in serum chromium. 
Lipid Metabolism 
Evidence from animal and human studies indicates an 
alteration in lipid metabolism in the presence of chromium 
deficiency affecting the development of atherosclerosis and 
serum concentrations of cholesterol and triglycerides. 
Chromium deficiency has been linked to an increase in serum 
cholesterol and aortic plaque in animals. In a study 
reviewed by Anderson, chromium supplementation in a 
low-chromium diet (1 ugfml or 5 ugfml) decreased the serum 
cholesterol level in rats and reversed the tendency toward 
13 
increasing cholesterol levels with advancing rage. In 
addition, chromium-supplemented animals had 17% less aortic 
plaque than the control animals at the end of their natural 
lives (Anderson 1987). Abrahamr,et al. (1982) fed high-
cholesterol diets to rabbits to induce atherosclerotic 
plaques. Subsequent daily administration of 20 ug of 
potassium chromate intraperitoneally led to a decrease in 
aortic cholesterol concentration and a reduction of aortic 
plaques. 
However, Donaldson et al. (1985) found no significant 
differences between rats fed for twelve months either 
chromium-depleted (60 to 100 ugjkg) diet or 
chromium-supplemented (5000 ugjkg diet) for plasma glucose, 
total cholesterol, or triglycerides. A similar finding was 
reported by Preston et al. (1976) studying the effect of 
chromium supplemented diets (0.5 ppm or 50 ppm as 
CrC13 .6H20) on non-pregnant, pregnant, and lactating guinea 
pigs. Their findings ~ stated " •... serum cholesterol appeared 
to be more affected by pregnancy and generation of guinea 
pigs than by the level of dietary chromium." 
Human studies have shown improvements in serum lipid 
parameters when subjects were supplemented with trivalent 
chromium. Riales and Albrink (1981) showed a significant 
increase in HDL cholesterol levels among subjects consuming 
200 ug chromium as CrC13 .6H2o in 5 ml of water five days a 
week for twelve weeks. Triglyceride levels were also 
significantly reduced in the experimental group when 
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compared to the control at 12 weeks. Abraham et al. (1992) 
studied the effects of oral supplementation of 250 '' 'Ug 
chromium as chromium chloride in 5 ml of water on patients 
with and wi,thout non-insulin dependent diabetes 'mellitus 
(NIDDM) for 7 to 16 months. Findings included a significant 
decrease in serum triglycerides and a signl'ficant increase 
in HDL cholesterol with no change in total cholesterol or 
glucose. The findings were not significantly different 
between diabetic and non-diabetic subjects. The extended 
length of study was designed to overcome any transitory 
changes due to supplementation. A Zimbabwean study of 
thirty-nine diabetic subjects supplemented with -600 ug 
trivalent chromium in water for three months found a 
consistent increase in HDL cholesterol levels in the 
supplemented group and a decrease in HDL cholesterol among 
the control group (Mossop 1983). A study of 24 elderly 
subjects (including eight with NIDDM) found a 12% decrease 
in serum cholesterol among the experimental group fed 9 
grams of brewers yeast daily for eight weeks. Among 
subjects with hypercholesterolemia (> 300 mgjdl), an 18% 
decrease in total cholesterol and an average 20% decrease in 
serum triglycerides were noted. Total lipids declined in 
all experimental subjects with the greatest decline among 
the group with hypercholesterolemia (Offenbacher & Pi-Sunyer 
1980). 
Uusitupa et al. (1983) found no significant differences 
in serum lipid parameters among volunteers with NIDDM 
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supplemented with 200 ug tr:ivalent~!.chromium daily for 6 
weeks. These findings may help to substantiate the concept 
that chromium supplementation is only effective in chromium 
depleted subjects. In a double blind·crossover study, 
Anderson and co-workers (19B3) found no effect on any serum 
lipid .levels for either sex when normoglycemic subjects were 
supplemented for three months with 200 ug chromium as 
chromic chloride. 
Tissue Chromium Concentration 
Chromium concentrations of tissues in normal and 
genetically diabetic (db/db) mice were compared by Berggren 
and Flatt (1985a). Tissue chromium concentrations in 
kidney, muscle and exocrine pancreas were not significantly 
different than that of ·the endocrine pancreas in diabetic 
mice. In a subsequent study, . Berggren and Flatt (1985b) 
found an increase in non-pancreatic tissue chromium 
concentrations in lean .mice 96 hours after intraperitoneal 
injection of 2 mg trivalent chromium/kg body weight. This 
administration. of exogenous chromium failed to affect tissue 
accumulations in the obese mouse indicating either a rapid 
chromium excretion or an inability to utilize chromium (III) 
rather than a deficiency per se. 
Tissue concentrations of rats fed chromium (III) 
deficient (0.03 mg Crjkg) diet for three weeks were not 
different from controls fed 1 mg Crjkg diet with the 
exception of significantly lower (44%) pancreatic chromium. 
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Possible explanations for these results included tissue 
saturation prior to the onset of the deficient diet, an 
increase in absorption among those animals ~'fed the chromium 
deficient diet, or variation among species between mice and 
rats (Flatt et al. 1989). 
Donaldson et al. (1985) compared the effects of high 
sucrose, high cholesterol, low chromium diets to similar 
chromium supplemented diets. Sprague- Dawley rats fed the 
low-chromium diets for eighteen months had significantly 
lower kidney chromium concentrations than those fed the 
chromium-supplemented diet. Seaborn and Stoecker (1989) 
studied the effect of various sources of carbohydrate on 
chromium absorption and tissue concentration. Obese mice 
had higher chromium concentration in testes, bone and spleen 
when compared to lean mice. Kidney concentration was not 
affected by obesity. Lean mice showed greater effects of 
diet on liver chromium concentration than did the obese 
model. Animals fed starch showed greater uptake of 51cr 
from 51crcl3 and generally greater tissue chromium than did 
animals fed sucrose, glucose or fructose, indicating that 
dietary carbohydrate affects chromium absorption and 
retention. 
Variations Among Studies 
Results of both animal and human studies on chromium 
have been equivocal. Variations in methods, initial 
glycemic or lipid status of subjects, animal model 
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selection, length of study, dietary intake, source of 
chromium, amount of supplementation, and sources of 
contamination may affect the outcome of the research and may 
help to explain the inconsistent results among similar 
experiments. 
Manganese 
Essentiality 
Manganese has been found to be essential in all animal 
species studied; deficiency has been documented in mice, 
rats, guinea pigs, poultry, pigs, and cattle (Hurley & Keen 
1987). Symptoms of deficiency shared by the offspring of 
all species include impaired growth, skeletal malformations, 
decreased reproductive function, neonatal ataxia, and 
defective lipid and carbohydrate metabolism. severity of 
symptoms vary with degree and duration of the deficiency and 
with the developmental period coinciding with the deficiency 
(Hurley & Keen 1987}. 
Manganese deficiency in humans has not been clearly 
established; the widespread availability of manganese in the 
food supply in relation to need and the tendency of the body 
toward homeostatic control of manganese concentrations in 
the tissues may be partial explanations. Manganese is known 
to function as an activator for a variety of metalloenzymes 
including hydroxylases, kinases, decarboxylases, and 
transferases. Activation of these enzyme systems in vitro 
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may not be specific to manganese. ,<·Manganese may be replaced 
by a number of other divalent cations, primarily magnesium, 
thereby reducing or eliminating potential deficiency signs 
stemming from these systems. 
Carbohydrate Metabolism 
Defects in carbohydrate metabolism are common among the 
offspring of manganese-deficient animals. The varied role 
of manganese in carbohydrate metabolism has provided several 
possible explanations for alterations -observed in the 
manganese-deficient animal. Suggested mechanisms include 
the impairment of insulin synthesis and secretion, a 
decrease in insulin sensitivity, destruction of pancreatic 
beta cells, and a decrease in gluconeogenesis (Keen & 
Zidenberg-Cherr 1990). 
Everson and Shrader (1968) studied the effects of 
manganese deficiency in guinea pigs. Fasting glucose of 
deficient animals averaged 40 mgfdl higher than controls. 
Results of glucose tolerance tests showed elevated blood 
glucose among deficient animals. Blood glucose remained 
elevated throughout the test period and in some cases 
exceeded fasting val ues by more than 50 mgjdl after four 
hours. Control animals exhibited more normal tolerance 
curves with blood glucose returning to fasting levels within 
two to three hours. Subsequent supplementation of the 
deficient animals with adequate dietary intakes of manganese 
reversed the impaired glucose utilization. 
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Based on Everson and Shrader's work, Baly et<al. ('1984) 
hypothesized that "manganese deficiency might result -"in 
altered insulin secretion." Reduced insulin synthesis, 
secretion or sensitivity were ;cited as possible mechanisms 
of manganese acti on. Male and ·.'female weanling 
Sprague-Dawley rats were fed diets containing either 45 ug 
Mnfg (control) or 1 ug Mn/g beginning at 21 days of age. At 
three months, the females were mated with stock fed males; 
males were used for comparative effects with the 2nd 
generation offspring in carbohydrate studies. Both first 
and second generation of manganese-deficient rats showed 
lower fasting blood insulin levels than controls. In second 
generation rats, increasing blood glucose levels failed to 
stimulate adequate insulin secretion. No differences were 
noted between first generation manganese-deficient rats and 
controls. The authors concluded that the lack of effect of 
manganese-deficiency on the first generation rats suggests 
that the abnormal glucose tolerance is developmental and 
that deficiency must "be present while the animal is in 
utero or during its suckling period, or both." They 
attribute the deficiency effects to abnormalities in 
pancreatic development, beginning around the twelfth day of 
embryonic development. Other potential causes cited 
included damage or destruction of pancreatic beta cells by 
free radicals due to reduced manganese superoxide dismutase 
(MnSOD) activity in manganese deficiency. Initial release 
of preformed insulin was only 76% that of controls in second 
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generation rats. Secondary release, includingc preformed and 
newly synthesized insulin, was also significantly lower in 
the offspring of deficient rats. The degree of inhibition 
in insulin secretion increased· as glucose stimulation was 
extended, suggesting an impaired biosynthetic mechanism. 
Manganese functions as part of the metalloenzymes 
pyruvate carboxylase (PC) and phosphoenolpyruvate 
carboxykinase (PEPCK), both key enzymes in gluconeogenesis. 
Blood glucose levels of the neonatal rat are dependent upon 
gluconeogenesis during the first days postpartum due to the 
low carbohydrate, high fat concentrations of rat milk. Baly 
et al. (1985) investigated the relationship between the 
activity of PEPCK, PC and blood glucose levels in the 
neonates of manganese-deficient rats and assessed pancreatic 
function in the adult offspring of manganese-deficient rats. 
Results of the studies included the following: impaired 
gluconeogenesis in the neonatal period, possibly related to 
decreased PEPCK activity; decreased glucose tolerance; low 
plasma insulin levels; and depressed insulin output and 
synthesis. 
In a follow-up study (Baly et al. 1985b), the effect of 
glucose on insulin biosynthesis and secretion in the 
presence of manganese deficiency was investigated. A 
glucose concentration of 300 mgfdl stimulated the production 
of 19.4 ug insulin per gram of pancreas compared to 3.4 ugfg 
produced by the pancreas of manganese-deficient rats. In 
addition, no degradation of insulin occurred in the control 
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animals but 7.8 ug of insulin per gram of pancreas was 
degraded by the deficient pancreata after 80 minutes. These 
results were significant in that they were the >first to 
demonstrate 'a role for manganese .in insulin biosynthesis and 
degradation. 
A .study by Baly et al. (1990) examined insulin binding 
and glucose transport ~n adipose tissue of manganese-
deficient and control rats. Both basal and insulin 
stimulated glucose uptake were ~ound to be impaired in the 
manganese-deficient rats. A lower ·maximal transport 
velocity in these animals suggests a reduction in the number 
of transporters ava~lable compared to control rats. Also 
noted was a decrease in the number of insulin receptors in 
the manganese-deficient rats suggesting a loss of insulin 
sensitivity in the peripheral tissues. 
Lipid Metabolism 
A variety of defects in lipid metabolism related to 
manganese deficiency have been documented. Fahim et al. 
(1990) studied the effects of diets varying in manganese and 
magnesium content on total cholesterol levels in Swiss 
albino mice. Normal (control)" diets contained 335 mg 
magnesium and 53 .mg manganese/kg and deficient diets 
contained 110 mg magnesium and 1 mg manganese/kg. Mice were 
fed the experimental diets for five weeks. Only the animals 
fed the diet deficient in both magnesium and manganese 
showed a significant increase in serum cholesterol 
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(p < 0.001) when compared to controls. Groups deficient in 
only manganese or only magnesium showed no significant 
difference in total cholesterol. The authors also found 
that the combined effects of dietary manganese and magnesium 
deficiency caused a 46% increase in liver lipid_content when 
compared to controls. 
Baly et al. (1990) studied the effect of manganese 
deficiency on the conversion of glucose to triglycerides in 
the adipocytes of offspring of Sprague-Dawley rats. No 
difference between basal rate of.conversion of glucose to 
triglyceride was observed between manganese-deficient and 
control animals. However, insulin stimulated conversion was 
significantly lower in the deficient animal averaging 26% 
less than the conversion rate of controls. 
Research on the relationship between manganese and 
lipid metabolism has been reviewed by Hurley and Keen 
(1987). One study showed that a manganese-deficient diet may 
produce excessive fat deposition in mice. Addition of 
manganese to rat liver in vitro resulted in a pronounced 
increase in cholesterol synthesis. Another study cited 
found that male weanling Sprague-Dawley manganese-deficient 
rats displayed lower levels of cholesterol in plasma and 
liver than control animals. Similar findings were reported 
where a manganese-deficient diet in human adult men was 
related to an increased incidence of hypocholestrolemia. 
23 
Tissue Concentration 
Tissue concentrations of manganese are uniformly 
distributed throughout the body with little variation 
between species. Keen et al. (1985) studied the effect of 
intraperitoneal injections of manganese on tissue mineral 
concentrations. After two weeks on standard laboratory 
diet, Sprague-Dawley rats were injected with 2.5 - 4.0 mg 
MnC12 /kg body weight and sacrificed at various times 
post-injection. Tissues analyzed included liver, kidney, 
brain, and pancreas. All tissues were found to have a 
significant increase in manganese concentration; the 
increase was dose dependent and maximal levels were found to 
occur between 30-60 minutes post injection. Davis et al. 
(1992) analyzed tissue concentrations in rats fed 54Mn and 
in rats injected intraportally with 54Mn after being fed 
varying levels of manganese and iron for seven weeks. 
Animals fed 54Mn retained significantly less of the isotope 
after 4 days than those receiving 54Mn intraportally 
regardless of the dietary manganese and iron levels. 
Manganese-deficient animals retained more of the isotope 
regardless of whether it was fed or injected. Dietary 
manganese significantly affected tissue distribution of the 
isotope with an increased proportion appearing in the liver 
and a lower proportion appearing in pancreas, kidney, bone 
and muscle of deficient animals than in animals fed adequate 
or high levels of manganese. The authors concluded that the 
mucosal cell was the likely site of control of manganese 
homeostasis. 
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Kennedy et ·~l. (1986) found that the obesity of the 
C57BL/6J (ob fob) mice is associated with decreased 
concentrations of. manganese, zinc, copper, ·and iron in 
several tissues and these alterations are independent of the 
animals' sex. Tissue manganese concentrations were not 
significantly different between obese and control at five 
weeks but by twenty-two weeks, concentrations in liver, 
small intestine and bone were significantly reduced in the 
obese mice. Tissue manganese concentrations of first and 
second generation rats fed manganese-deficient diets were 
significantly lower in liver, kidney, heart, and pancreas 
than those of controls. No significant differences were 
seen between copper, zinc or liver iron concentrations of 
the groups (Baly et al. 1990) . 
Variations in the Obese (objob) Model 
The obese (objob) mouse provides an interesting model 
for attempting to understand similar interactions that occur 
in human diabetes. These mice display characteristics 
similar to those found in the human experience. 
Characteristics of the obese mouse include hyperinsulinemia, 
hyperphagia, and hyperplasia and hypertrophy of pancreatic 
beta cells. Secondary characteristics include 
hyperglycemia, obesity and severe diabetes (Coleman ·1982). 
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A longitudinal hormonal profile of the obfob mouse 
model by Garthwaite et al. (1980) concluded that 
hyperinsulinemia and hyperadrenocorticism were 
characteristic throughout the life span while plasma glucose 
levels were elevated at 5-20 weeks and again at 62 weeks of 
-< ,' 
age. Insulin resistance was -also found to improve after 20 
weeks of age. 
The obese mouse is further characterized by an 
increase in both size and number of adippcytes. There is an 
increase in the activity of insulin-dependent enzymes and 
the rate of lipogenesis in the liver and adipose tissue is 
more than twice that of lean models. It has been suggested 
that the progressive hyperglycemia with an .inverse number of 
active insulin receptors may protect the obese model from 
potentially fatal hypoglycemia· should circulating insulin 
levels be fully effective. The loss of insulin receptors is 
thought to be associated with the increase in 
gluconeogenesis which contributes to the hyperglycemic state 
of th.e obese mouse model (Coleman 1982). 
Studies have shown that obese mice may consume as much 
as 75% more food per day than lean controls when food is 
available ad libitum (Kennedy et al. 1986). Despite the 
dramatic increase in intake, tissue levels of some trace 
elements remain below the level of the control animals 
indicating "alterations in the tissue distribution and 
metabolism of endogenous micronutrients" (Kennedy et al. 
198 6) . 
CHAPTER I;II 
CHROMIUM AND MANGANESE: DEPLETION EFFECTS 
IN GENETICALLY OBESE (obfob) MICE 
ABSTRACT 
Forty male weanling genetically obese mice 
(C57BL/6J-OB) (obfob) and their lean littermates were 
assigned to one of four experimental diets. Groups ·included 
low .chromium- low manganese (-Cr/-Mn), low chromium-
adequate manganese (-Cr/+Mn), adequate chromium- low 
manganese (+Crf-Mn), or adequate chromium- adequate 
manganese (+Cr/+Mn). 
Animals were maintained on ·the diets for a period of 
thirty-five days. Body weight and weight gain were 
increased by obesity with weight gain also showing 
significant effects due to manganese and an int~raction 
between obe'sity and chromium. Plasma glucose, insulin, 
corticosterone, cholesterol, and glycosylated hemoglobin 
were all elevated in obese animals compared to lean. 
Chromium supplementation resulted in significantly higher 
serum cholesterol levels. Glycosylated hemoglobin was 
significantly higher among +Mn animals. Liver 
concentrations of manganese, iron, zinc, calcium, and 
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magnesium were significantly lower in onese ''-mice tha:n in 
controls. Manganese ·supplementation resulted in higher 
liver manganese concentrations ('P < 0.001) in lean and obese 
groups. Kidney manganese and zinc were significantly lower 
in the obese animals; kidney copper increased (p < ' 0.0005} 
in the obese animals. Animals supplemented with manganese 
had .significantly higher concentrati ons of kidney manganese 
and -lower concentrations of zinc and -calcium. overall, no 
significant effects of .dietary chromium andjor manganese 
were observed on selected parameters of carbohydrate or 
lipid metabolism in the obese mouse. Further research is 
warranted. 
Introduction 
Abnormalities in carbohydrate and lipid metabolism are 
characteristic complications of non-insulin dependent 
diabetes mellitus (NIDDM). Hyperglycemia, hyperinsulinemia, 
and hypercholesterolemia are among the contributing factors 
to long term complications of the disease. Trace minerals 
are known to participate in the metabolism of both 
carbohydrate and lipid and studies have shown that 
deficiencies of certain trace minerals may induce symptoms 
similar to those of NIDDM {Mertz 1993). 
The essentiality of chromium in animals was established 
in the 1950's when chromium was identified as the active 
component in glucose tolerance factor (Schwarz & Mertz 
1959). An Estimated Safe and Adequate Daily Dietary Intake 
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(ESADDI) for chromium was added to the Recommended Dietary 
Allowances in 1980 (National Research Council 1989). A 
recent review examined fifteen studies evaluating the 
effects of chromium supplementation. Conclusions of the 
review suggested that chromium deficiency results in insulin 
resistance which can be improved with chromium 
supplementation and that such deficiencies do occur in the 
United States and elsewhere and may be an important cause of 
insulin resistance in those populations (Mertz 1993). 
Manganese has been found to be essential in all animal 
species studied. Defects in carbohydrate and lipid 
metabolism are among the complications common to the 
offspring of manganese-deficient animals (Hurley & Keen 
1987). The varied role of manganese in carbohydrate 
metabolism has provided several possible explanations for 
the alterations seen in the manganese-deficient animal. 
Suggested mechanisms include the impairment of insulin 
synthesis and secretion, a decrease in insulin sensitivity, 
destruction of pancreatic beta cells, and a decrease in 
gluconeogenesis (Keen & Zidenberg-Cherr 1990). Manganese is 
known to function as an activator for a variety of 
metalloenzymes including hydroxylases, kinases, 
decarboxylases, and transferases (Hurley & Keen 1987). 
Activation in vitro is not specific to manganese. Manganese 
may be replaced by a number of other divalent cations, 
primarily magnesium, thereby reducing or eliminating 
potential deficiency signs stemming from these ~ys:t;.ems 
(Hurley & Keen 1987). 
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Previous research into .tll.e relationship between. ;trace 
minerals and altered metabolism of car})opydrate and lipid in 
diabetes has .not included studies of the :PO~ined effects of 
chromium and manganese depletion. Prior research in this 
laboratory involved the effects of low .chromium and low 
manganese diets on rats with streptozotocin (STZ) induced 
diabetes. Four weeks post injection, only those animals fed 
adequate amounts of both chromium and manganese displayed 
normal fasting glucose levels. In order to eliminate the 
possible effects of trace minerals on the efficacy of STZ, 
this study used the genetically ·obese mouse. This 
genetically obese model C57BL/6J (obfob) is characterized by 
obesity, hyperglycemia, hyperinsulinemia, and 
hyperadrenocorticism (Coleman 1982, Garthwaite 1980) making 
it a good model to examine the effects of chromium and 
manganese depletion. 
Materials and Methods 
Forty weanling male genetically obese (obfob) mice 
(C57BL/6J-OB) and their lean littermates were received and 
held for a three-week adaptation period on the American 
Institute of Nutrition (AIN) diet for mice and rats with the 
AIN mineral mix modified in our laboratory to have no added 
chromium and to be low in manganese. The diet contained 50% 
dextrose, 20% casein, 15% cornstarch, 5% celufil, 5% corn . 
oil, 3.5% modified AIN mineral mix, 1.0% AIN vitamin mix, 
0.3% DL-methionine, and 0.2% choline bitartrate. Diet and 
deionized water were provided ad l ,ibitum. Animals were 
housed in plastic cages and fed from ceramic cups. 
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After the adaptation period, animals were assigned to 
one of four .diet groups for six weeks. Groups included low 
chromium- low manganese (-Cr/-Mn), low chromium- adequate 
manganese (-Cr/+Mn), adequate chromium - low manganese 
(+Crj-Mn), or adequate chromium- adequate manganese 
(+Cr/+Mn). Low chromium diets were analyzed by atomic 
absorption spectrophotometer and found to contain < 20 ug 
Cr/kg diet chromium. Basal diet with adequate chromium . 
added contained 2 mg Crfkg diet as CrC13 .6H2 o; low and 
adequate manganese diets were supplemented with 3.0 or 55 mg 
Mnfkg diet as Mnco3 respectively. 
Prior to autopsy, animals were ·food-deprived for ten 
hours and then weighed. The mice were anesthetized with 
Metofane (methoxyflurane) and were exsanguinated by cardiac 
puncture using heparinized syringes; samples were chilled 
and centrifuged to obtain plasma samples. Plasma was frozen 
for subsequent analyses. Liver, kidney, spleen, heart, 
testes, lung, epididymal fat pad and thymus tissues were 
removed carefully to avoid chromium contamination, wrapped 
and frozen for mineral analysis. 
Insulin was assayed using Equate RIA Insulin Double 
Antibody kits (Binax, Inc. South Portland, ME) (Crowley & 
Garbien 1974). Glucose was analyzed using the glucose 
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oxidase method (Procedure No. 510, Sigma Chemical, st. 
Louis, MO) as described by Kadish et al. ( 1:967) ~. 
Corticosterone was determined by radioimmunoassay using 
Coat-A-Count Rat Corticosterone ''kit (Diagnostic Products 
Corp. , Los Angeles., CA) . Glycohemog1obin ,,was determined 
using. the Isolab GlycAffin columns. Cholesterol was 
analyzed by the enzymatic method ,described by Allain et al. 
(1.974). ' 
Tissues were analyzed using the method described by 
Hill et al. (1986). After ashing, samples were diluted with 
0.5% nitric acid and analyzed at 357.9 nm using a 
Perkin-Elmer Model 5000 atomic absorption spectrophotometer 
with a graphite furnace and Zeeman background correction. 
The Statistical Analysis System (SAS) was used to 
evaluate treatment effects. The generalized linear model 
(GLM) was used for analysis of variance and least squares 
means determination. Data were analyzed using a split-plot 
design with a 2 X 2 factorial subplot. Obesity was the main 
effect and dietary chromium and manganese levels were 
subplot factors. 
Results 
Body weight was significantly greater in obese mice 
when compared to lean {Table 1). Mean body weight for the 
obese group was 44.3 g compared to a mean of 29.8 g among 
lean mice. Mean weight gain among obese mice was 15.6 g; 
mean weight gain among lean mice was 7.2 g. Mice fed a -Mn 
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diet showed a greater weight gain than did those fed the ·+Mn 
diet. A significant interaction between the obese gene and 
dietary chromium was observed in mean weight gain. Chromium 
supplementation resulted in lower total weight gain among 
obese mice. Similar ·results were not :observed among lean 
animals • . 
Obesity significantly increased serum levels of 
glucosei glycosylated hemoglobin, corticosterone, insulin, 
and cholesterol (Table 2). Manganese significantly affected 
glycosylated hemoglobin with the higher levels occurring 
among +Mn animals. Cholesterol levels were higher 
(p < 0.05) in the +Cr group. 
Liver and kidney ctissues were analyzed for mineral 
concentrations. All liver mineral concentrations analyzed 
except chromium were significantly reduced among obese 
animals (Table 3). Liver chromium concentrations tended to 
be lower in obese animals (p < 0.07). Significant 
interactions were observed between the obesity gene and 
dietary manganese. Low manganese diets resulted in 
significantly lower concentrations of liver manganese in 
both obese and lean mice. Liver iron concentrations reached 
near significance (p < 0.07) due to manganese with the 
higher concentrations of iron occurring in the -Mn group. 
No other significant effects of dietary treatments or 
obesity were observed. 
Chromium, iron and magnesium concentrations were not 
significantly affected by obesity or dietary treatments in 
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kidney (Table 4). Kidney manganese was signiffcant for both 
obesity and manganese, the higher concentrations occurring 
among lean and +Mn respectively. Kidney zinc concentrations 
were significant with respect to obesity and manganese, zinc 
levels were higher among lean and "manganese-deprived 
animals. Copper levels were significantly 'higher among 
obese mice. Calcium concentrations were lower among +Mn 
animals but -showed no significance due to obesity. 
Discussion 
Final body weights for lean and obese animals were -
29.8g and 44.3g respectively. No significant effects of 
dietary chromium and manganese on body weight were observed. 
Similar findings ·by Baly et al. (1990) showed no significant 
difference in body weight between manganese-deficient and 
control groups of Sprague-Dawley rats. 
Manganese-supplemented animals showed a lower total 
weight gain than -Mn· animals. In contrast, Fahim et al. 
(1990) showed a 29% reduction in weight gain among 
manganese-deficient swiss albino mice when compared to 
controls. Diets containing normal (0.053 g Mn/kg) dietary 
amounts of manganese showed no significant effect on weight 
gain. 
Chromium supplementation resulted in a significant 
(p < 0.03) reduction in weight gained in the obese group 
compared to control. No differences in weight gain were 
observed by Flatt et al. (1989) in Wistar rats fed chromium 
deficient (0.03 mgfkg) or chromium supplemented (1 .mgfkg) 
diets. 
Plasma cholesterol levels were higher (p < 0.0001) in 
obese mice. Chromium supplemen~ation resulted in higher 
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(p < 0.05) plasma cholesterol levels. T~ese findings 
contrast with findings of elevated cholesterol with 
increasing age among rats fed low chromium ~iets (Anderson 
1987). Abraham et al. (1992) showed reduced aortic plaque 
in rabbits given trivalent chromium by intraperitoneal 
injection. Other studies using rats and guinea pigs (Evans 
et al. 1973, Preston et al. 1976) have shown no relationship 
between chromium intakes and serum cholesterol. 
No effect was found of dietary manganese on plasma 
cholesterol. These results were similar to the findings of 
Fahim et al. (1990). swiss albino mice showed no effect in 
serum cholesterol levels when manganese levels in the diet 
were decreased to 0.001 gram Mn/kg diet for five weeks. In 
another study reviewed by Hurley and Keen (1987), a decrease 
in serum cholesterol occurred among male Sprague-Dawley rats 
fed a diet deficient in manganese. 
Serum glucose and glycosylated hemoglobin 
concentrations were significant;ly elevated among the obese 
mice compared to lean. Elevated levels of glucose are 
consistent with known characteristics of the obfob mouse 
model (Coleman 1982, Garthwaite et al. 1980). Glucose 
levels were not affected by chromium or manganese. 
Glycosylated hemoglobin was not affected by chromium; 
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however a significant (p < 0.02) effect due to manganese was 
observed with +Mn animals showing higher concentrations. In 
contrast are findings of Everson and Shrader {1968) in which 
higher fasting glucose levels were found among guinea pigs 
fed a low manganese diet ~hich reverted to normal levels by 
supplementation with adequate dietary manganese. Research 
has shown defects in carbohydrate metabolism to occur 
predominantly in second generation manganese-deficient 
animals. 
Serum insulin was higher (p < 0.0001) in obese mice. 
This finding is consistent with other studies of the obese 
mouse model {Coleman 1982, Garthwaite et al. 1980). In our 
study, manganese -had no effect on serum insulin 
concentrations. In contrast, Baly found lower circulating 
insulin levels among both first and second generation 
manganese-deficient rats when ·compared to controls. The 
second generation rats were unable to secrete adequate 
insulin in response to increasing blood glucose levels, a 
response not seen in the first generation test animals (Baly 
et al. 1984) . 
Our results concur with those of Flatt et al. (1989} 
who found no relationship between dietary chromium intakes 
and body weight, glycosylated hemoglobin, plasma glucose or 
plasma insulin in Wistar rats fed a low chromium {0.03 
mgjkg) diet for 32 days post-weanling when compared to 
controls. 
Corticosterone levels were higher (p ,< 0.0001) among 
the obese mice. These findings are consistent with other 
research involving the C57BL/6J objob mouse model. Elevated 
levels of adrenocorticotropic hormone (ACTH) in young obese 
mice were reported by Garthwaithe et al. (1980). This early 
onset elevation of ACTH correlates with the . elevated insulin 
and glucose levels also seen in the obese model. 
Corticosterone levels were not affected by the variation of 
dietary manganese and chromium in our study. 
All liver mineral concentrations except chromium 
(p < 0.07) were significant with respect to obesity, lower 
concentrations occurring among. the obese animals. This may 
be a result of increased excretion, failure to store .or 
both. Similar results were found by Kennedy et al. ( 19 8 6) 
where lower concentrations of zinc, copper, iron and 
manganese were found in the liver of the obese mouse when 
compared to the controls at 22 weeks of age. No significant 
differences were noted in tissue concentrations between the 
two groups at five weeks indicating a progression of tissue 
depletion with age among obese animals. 
Liver chromium concentrations were not affected by 
dietary chromium or manganese. Liver chromium stores tended 
to be lower (p < 0.07) in obese animals. Berggren and Flatt 
(1985a) found no significant difference between liver 
chromium concentrations of genetically diabetic-obese mice 
and their lean littermates. Similar findings in a follow-up 
study using objob mice found no difference in chromium 
levels of the liver or kidney between obese and lean ,;mice 
(Berggren & Flatt 19B5b). 
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Liver iron concentrations tended to be lower (p < 0.07) 
with respect to manganese, lower tissue stores occurring in 
the +Mn group. Interactions between iron and manganese have 
been investigated in several species. Results indicate that 
the two minerals compete for binding sites in the intestinal 
mucosa affecting absorption rates of both minerals (Hurley & 
Keen 1987). Davis et al. (1992) showed that high intakes of 
iron significantly decreased liver manganese concentrations 
by inhibiting the uptake of manganese by mucosal cells and 
thereby affecting total absorption. 
Liver manganese levels were lower in the obese -Mn 
group of animals (p < 0.0001). Liver manganese stores for 
obese -Mn mice were 29% of the lean -Mn group and 14% of the 
lean +Mn group. Liver manganese levels in lean -Mn mice 
were not different when compared to obese +Mn. Dietary 
manganese levels had a significant effect on liver manganese 
concentrations with +Mn animals showing significantly higher 
concentrations than the -Mn group. Similar results were 
found by Davis et al. (1992) who found an increase in liver 
manganese concentrations as dietary manganese level s were 
adjusted from deficient to adequate to high intake (0.9, 48 
or 188 ug Mn/g diet respectively) in Sprague-Dawley rats. 
Liver manganese concentrations were not significantly 
affected by chromium. 
38 
Kidney mineral concentrations were not as consistent as 
the liver with respect to obesity; manganese; zinc and 
copper showed the only significant effects. Kidney 
manganese and zinc levels were lower in obese than control 
mice; kidney copper concentrations were greater in obese 
mice. Chromium, iron, calcium and magnesium levels were not 
significantly different between obese and lean mice. 
Kidney manganese and zinc levels were also significant 
with respect to manganese supplementation. Kidney manganese 
levels were affected more by dietary manganese (49.23 vs 
93.04 ugmoljg, p < 0.0001) than obesity (74.93 vs. 67.32 
ugmoljg, p <0.03). Animals fed the +Mn diet showed 
significantly higher manganese levels in the kidney in both 
lean and obese animals although the obese animals had 
significantly lower concentrations than the lean mice. 
Kennedy et al. (1986) found no difference in kidney 
manganese levels at 5 and 22 weeks between lean and obese 
mice fed 61 ug Mn/g dry weight diet. 
Kidney zinc levels were significantly reduced in the 
obese group when compared to lean (1.05 vs 1.001 ugmoljg, 
p < 0.02). Animals fed the +Mn diet had significantly lower 
levels of zinc in the kidney when compared to the -Mn group 
(1.04 vs 1.00 ugmolfg, p < 0.02). Kidney zinc levels were 
not affected by chromium. 
Liver, spleen, and epididymal fat pad tissue weights 
were significantly increased due to obesity and heart was 
decreased (Table 6). No other significant effects of 
dietary treatment or obesity were seen on tissue weights. 
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In conclusion, feeding diets low in chromium and 
manganese to genetically obese mice and lean controls had 
little effect on the parameters of carbohydrate and lipid 
metabolism measured. Several other researchers (Anderson 
1987, Baly et al. 1984, Everson and Shrader 1968, Fahim et 
al. 1990, Flatt et al. 1989) using different protocols have 
shown effects of manganese or chro~ium on carbohydrate and 
lipid metabolism. Differences may be the result of wide 
variability in this study, inadequate trace mineral 
depletion, or failure to assay. the more sensitive 
parameters. Further investigation might include additional 
testing of plasma glucose, insulin, cholesterol and 
glycosylated hemoglobin prior to and during initiation of 
the feeding regimen. In addition, a glucose challenge prior 
to sacrifice and examination of pancreatic physiology might 
yield significant findings. 
.r:-
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TABLE #1 
Final body weight and weight gain of obese and lean mice 
fed diets with low and adequate chromium and manganestJ 
Final Body Weight Weight Gain 
Grams 
Main Plot Means 
OB 44.3 ± 0.5 15.6 ± 0.3 
Lean 29.8 ± 0.5 7.2 ± 0.3 
Subplot Means 
-Cr 37.1±0.4 11.56 ± 0.3 
+Cr 37.0±0.5 11.17±0.4 
-Mn 37.5 ± 0.4 11.85 ± o. 3 
+Mn 36.6 ± 0.5 10.87 ± 0.4 
Source of variation P-values 
Gene < 0.0001 < 0.0001 
Cr 0.74 0.43 
Mn 0.25 < 0.05 
Gene x Cr 0.53 < 0.03 
Gene x Mn 0.13 o. 77 
CrxMn 0.12 0.75 
Gene x Cr x Mn 0.21 0.11 
1values are least squares means± SEM (Gene, N =: 39-40, Cr, N = 39-40, Mn, N = 39-40) 
TABLE #2 
Plasma glucose, glycosylated hemoglobin (GHB), corticosterone, insulin and 
cholesterol of obese and lean mice fed diets with low and adequate chromium and manganese. 1 
Glucose GHB Corticosterone Insulin Cholesterol 
mmol/L % nmol/L pmol/L mmol/L 
Main Plot Means 
OB 11.14 ± 0.45 6.16±0.24 409.91 ± 35.63 565.17 ± 46.91 6.27±0.16 
Lean 8.30 ± 0.48 4.08 ± 0.24 167.26 ± 39.00 92.63 ± 51.05 4.03 ± 0.20 
Subplot means 
,::.. 
-Cr 10.10 ± 0.50 5.27 ± 0.24 321.66 ± 255.51 312.24 ± 48.60 5 .oo ± 0.17 ,..... 
+Cr 9.32 ± 0.47 4.96 ± 0.24 255.51 ± 37.60 345.55 ± 49.41 5.40±0.18 
-Mn 9. 78 ± 0.45 4.70 ± 0.28 246.50 ± 35.89 324.03 ± 48.00 5.29 ± 0.17 
+Mn 9.64 ± 0.47 5.54 ± 0.24 330.67 ± 38.88 333.76 ± 50.83 5.02 ± 0.18 
Source of variation P- Values 
Gene < 0.0003 < o. 0001 < 0.0001 < 0.0001 < 0.0001 
Cr 0.24 0.36 0.22 0.63 < 0.05 
Mn 0.083 < 0.01 0.12 0.89 0.30 
Gene x Cr 0.65 0.93 0.93 0.50 0.18 
Gene x Mn 0.61 0.39 0.81 0.80 0.76 
CrxMn 0.42 0.16 0.78 0.90 0.28 
Gene x Cr x Mn 0. 77 0.88 0.73 0.98 0.48 
lvalues are least squares means± SEM (Gene, N = 39-40, Cr, N =: 39-40, Mn, N = 39-40) 
TABLE #3 
Liver mineral concentration of obese and lean mice fed diets with low and adequate chromium and manganese1 
Cr Mn Fe Zn Ca Mg Cu 
urool/g umol/g urool/g urool/g uool/g DOOl/g umol/g 
Main plot means 
OB 0.84 ± 0.50 16.48 ± 1.10 2.23 ± 0.11 0.60 ± 0.02 1.63 ± 0.13 8.40 ± 0.45 0.12 ± o.oo 
Lean 2.18 ± 0.51 42.21±1.12 4.13±0.11 1.20 ± 0.02 3.02 ± 0.13 13.33 ± 0.46 0.27 ± 0.00 
Subplot means 
-Cr 1. 76 ± 0.50 28.90 ± 1.08 3.23 ± 0.11 0.88 ± 0.02 2.38±0.12 10.89 ± 0.44 0.18 ± o.oo 
J::- +Cr 1.30 ± 0.52 29.80 ±1.14 
N 
3.13±o.q 0.91 .± 0.02 2.27 ± 0.13 10.81 ± 0.46 0.20 ± o.oo 
-Mn 1.10 ± 0.51 17.89 ± 1.10 3.33±0.11 0.90 ± 0.02 2.18 ± 0.13 11.20 ± 0.45 0.19 ± o.oo 
+Mn 2.00 ± 0.50 40.80 ± 1.12 3.03 ± 0.11 0.89 ± 0.02 2.46 ± 0.13 10.50 ± 0.46 0 •. 19 ± o.oo 
Source of Variation P- Values 
Gene 0.07 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 
Cr 0.50 0.56 0.55 0.25 0.57 0.90 0.15 
Mn 0.24 < 0.0001 0.07 0.58 0.13 0.30 0.70 
Gene x Cr 0.14 0.58 0.35 0.33 0.46 o. 72 0.88 
Gene x Mn 0.86 < 0.0006 0.60 0.82 0.48 0.54 0.85 
CrxMn 0.83 0.63 0.88 0.84 0.92 0.43 0.96 
Gene x Cr x Mn 0.91 0.23 0 . 58 0.84 0.92 0.41 0.98 
1Values are least squares means ± SEM (Gene, N::: 39-40, Cr, N:::: 39-40, Mn, N = 39-40) 
TABLE 14 
Kidney mineral concentration of obese and lean mice fed diets with low and adequate chromium and manganese1 
Cr Hn Fe Zn Ca. Hg Cu 
UTJX)l/g umol/g umol/g umol/g mmol/g TmX>l/g umol/g 
Main Plot Means 
OB 13.14 ± 1. 76 67.32 ± 2.11 5.14 ± 0.20 1.01 ± 0.01 5.68±0.16 16.46±0.42 0.26 ± 0.00 
Lean 12.36 ± 1.80 74.93 ± 2.14 5.10 ± 0.20 1.05 ± 0.01 5.44 ± 0.16 15.48 ± 0.42 0.24 ± o.oo 
Subplot Means 
-Cr 12.01 ± 1.73 70.00 ± 2.07 5.20 ± 0.20 1.01 ± 0.01 5.61 ± 0.20 15.65 ± 0.41 0.25 ± o.oo 
.t- +Cr 13.50 ± 1.82 72.25 ± 2.18 5.04 ± 0.20 1.03 ± 0.01 5.52 ± 0.20 16.28 ± 0.43 0.26 ± o.oo w 
-Hn 14.08 ± 1. 76 49.23 ± 2.11 4.91 ± 0.20 1.04 ± 0.01 5.88 ± 0.16 15.85 ± 0.42 0.25 ± 0.00 
+Mn 11.42 ± 1.80 93.04 ± 2.15 5.32 ± 0.20 1.00 ± 0.01 5.24 ± 0.20 16.08±0.42 0.25 ± o.oo 
Source of Variation P- Values 
Gene 0.76 < 0.03 0.87 < 0.02 0.25 0.11 < 0.0005 
Cr 0.56 0.45 0.59 0.26 0.66 0.30 0.13 
Hn 0.30 < 0.0001 0.15 < 0.02 < 0.01 0.71 0.85 
Gene x Cr 0.18 0.77 0.70 0.68 0.42 0.36 0.30 
Gene x Hn 0.96 0.67 0.87 0.47 0.60 0.31 0.90 
Crx Mn 0.33 0.88 0.22 0.25 0.32 0.43 0.30 
Gene x Crx Hn 0.26 0.48 0.76 0.66 0.53 0.64 0.96 
1Values are least squares means ± SEM (Gene, N = 39-40, Cr, N = 39-40, Mn, N = 39-40) 
TABLE #5 
Tissue weights of obese and lean mice fed diets with low and adequaJe chromium and manganese1 
Liver Kidney Spleen Heart Fat2 _ Thymus 
grams 
Main Plot Means 
OB 2.63 ± 0.05 0.32 ± 0.01 53.2 ± 1.8 0.12 ± o.oo 2.93 ± 0.04 40.3 ± 2.1 
Lean 1.04 ± 0.05 0.32 ± 0.01 64.1 ± 1.8 0.13 ± o.oo 0.94 ± 0.04 42.1 ± 2.1 
Subplot Means 
-Cr 1.86 ± 0 . 04 0.33 ± 0.01 61.0±1.7 0.13 ± o.o 2.00 ± 0.03 43.2±2.0 
+Cr 1.81 ± 0.05 0.31 ± 0.01 56.2 ± 1.8 0.12 ± o.o 1.90 ± 0.03 39.2 ± 2.1 
-Hn 1.84 ± 0.04 0.32 ± 0.01 58.6 ± 1.7 0.12 ± o.o 2.00 ± 0.04 40.5 ± 2.0 
.t-o 
&- +Hn 1.83 ± 0.05 0.32 ± 0.01 58.7 ± 1.8 0.13 ± 0.0 1.90 ± 0.04 42.0±2.1 
Source of Variation 
Gene < 0.0001 0.4252 < 0.0006 < 0.0084 < 0.0001 0.38 
Cr 0.45 0.18 0.06 0.11 0.14 0.17 
Hn 0.87 0.70 0.97 0.06 0.27 0.66 
Gene x Cr 0.39 0.61 0.80 0.95 0.14 0.73 
Genex Hn 0.40 0.78 0.12 0.60 0.27 0.90 
CrxMn 0.13 0.64 0.21 0.39 0.12 0.77 
Gene x Crx Mn 0.18 0.45 0.66 0.92 0.10 0.07 
1Values are least square means ± SEM (Gene, N = 39-40, Cr, N = 39 - 40, Mn, N = 39-40) 
2Epididymal fat pad 
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CHAPTER IV 
SUMMARY, CONCLUSIONS, AND, RECO!{MENDATIONS 
summary 
Forty male weanling genetically obese mice and forty 
lean control mice were randomly assigned to one of four 
experimental diets varying only in the amounts of chromium 
and manganese. After six weeks, animals were killed and 
selected tissues analyzed fo~ parameters reflecting 
carbohydrate and lipid metabolism. Weight gain was 
significantly affected by manganese and an interaction 
between obesity and chromium. Chromium supplemented animals 
had higher (p < 0.05) serum cholesterol levels compared to 
non-supplemented groups. Manganese supplementation resulted 
in higher levels of glycosylated hemoglobin. Manganese 
supplementation also resulted in higher liver manganese 
concentrations (p < 0.001) in lean and obese groups as well 
as higher concentrations of kidney manganese and lower 
concentrations of kidney zinc and calcium. Obesity 
significantly elevated plasma glucose, insulin, glycosylated 
hemoglobin, corticosterone and cholesterol while lowering 
concentrations of all trace minerals in the liver tissue. 
50 
51 
Conclusions and Recommendations 
The objective of the study was to investigate the 
effects and interactions which may occur in animals fed 
diets lacking in adequate amounts of chromium and manganese. 
Chromium showed no effect on glucose, insulin or 
corticosterone levels. Lack of effect may be due to the 
large variability within the study making significance 
harder to achieve. Although chromium concentrations in the 
diet were low, mere depletion of chromium may not be 
sufficient to cause an effect without an additional 
stressor. The lack of effect of manganese on serum glucose 
and insulin may also be partially explained by wide 
variability within the study. In addition, most pronounced 
effects of manganese deficiency occur in the offspring of 
manganese-deficient animals rather than during the first 
generation. Both variables may have been adversely affected 
by the age of the animals at autopsy. 
Future research in this area might benefit from 
additional testing of plasma parameters of glucose, insulin, 
glycosylated hemoglobin and cholesterol prior to and during 
initiation of the feeding regimen. In addition, a glucose 
challenge prior to autopsy may yield significant findings 
with respect to plasma glucose and insulin levels. 
Examination of pancreatic tissue post-autopsy, although 
difficult in the objob model, might provide interesting 
comparisons of possible alterations in pancreatic physiology 
due to chromium and manganese depletion. 
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APPENDIXES 
APPENDIX A 
Group means of weight gain and final body weight of obese and 
lean mice fed diets with low and adequate chromium and manganese1' 2 
Final weight Weight gain 
grams 
Lean 
-Cr -Mn 30.2±0.7 5.9 ± 1.4 
-Cr +Mn 28.8 ± 0.8 4.2 ± 1.4 
+Cr -Mn 28.0 ± o. 7 5.3 ± 1.4 
+Cr +Mn 28.7 ± 1.0 4.5 ± 1. 7 
Obese 
-Cr -Mn 45.4 ± 0.6 13.0 ± 2.4 
-Cr +Mn 43.5 ± o. 9 12.9 ± 2.2 
+Cr -Mn 45.1 ± 0. 9 12.8 ± 2.0 
+Cr +Mn 44.3 ± 0.6 10.0 ± 2.2 
1Mean ± SEM 
APPENDIX B 
Group means of plasma parameters in obese and lean 
mice fed diets with low and adequate chromium and manganese1 •2 
Glucose GHB Corticosterone Insulin Cholesterol 
(mmol/L) (%) (nmol/L) (pmol/L) (mmol/L) 
Lean 
-Cr -Mn 8.80 ± .080 4.26 ± 0.65 150.2±47.0 107.0 ± 19.2 4. 34 ± 0.16 
-Cr +Mn 8. 26 ± 1.00 4.30±0.70 248.2 ± 73.7 93.0 ± 15.0 3.66 ± 0.46 
+Cr -Mn 7.82 ± 0.91 3.37 ± 1.20 119.8 ± 35.8 84.4 ± 9.4 4.02 ± 0.23 
+Cr +Mn 8.31 ± 0.55 4.48 ± 0.33 169.7 ± 45.5 86.0 ± 7. 7 4.23 ± 0.22 
Obese 
-Cr -Mn 12.07 ± 1. 44 6.01 ± 1.67 413.3 ± 69.2 516.2 ± 121.8 6.00 ± 0.35 
-Cr +Mn 11.30±0.86 6.66 ± 2.50 487.4 ± 84.3 533.9 ± 108.7 5.72±0.33 
+Cr -Mn 10.64 ± 0.50 5.24 ± 1. 30 342.4 ± 66.3 602.0 ± 152.0 6. 85 ± 0.31 
+Cr +Mn 10.70±0.50 6.87 ± 1. 35 403.1 ± 99.0 625.0 ± 144.6 6.50 ± 0.50 
2Mean ± SEM 
APPENDIX C 
Group means of mineral concentrations of liver in obese and lean f'ice 
fed diets with low and adequate chromiwn and manganese1' 
Cr Mn Fe Zn Ca Mg Cu 
umol/g umol/g umol/g umol/g mmol/g rmnol/g ,, mmol/g 
Lean 
-Cr -Mn 2. 50 ± 3. 75 26.54 ± 8.06 4.30 ± o. 72 1.20 ± 0.10 3.04 ± 0.51 13.51 ± 2.43 0.26 ± 0.03 
·Cr +Mn 3.40 ± 6.28 57.84 ± 8. 40 4. 21 ± 1.07 1.18 ± 0.13 3.23 ± 0.93 13.47 ± 2.56 0.26 ± 0.03 
+Cr -Mn 0.55 ± o. 77 28.91 ± 6. 98 4.14 ± 0.41 1.20 ± 0.11 2.85 ± 0.50 14.36 ± 5.00 0.27 ± 0.01 
+Cr +Mn 2.02 ± 2.80 54.92 ± 9.00 3.89±0.89 1.20 ± 0.12 3.01 ± o. 40 12.10 ± 5.06 0.27 ± 0.04 
Obese 
-Cr -Mn 0.32 ± 0.35 7.57 ± 1.44 2. 43 ± o. 73 0.58 ± 0.10 1.44 ± 0.27 8.43 ± 1.44 0.11 ± 0.02 
-Cr +Mn 0.80 ± 1.70 23.60 ± 3. 56 2.00 ± 0.50 0.56 ± 0.08 1.82 ± 1.21 8.12 ± 1.00 o.u ± o.o1 
+Cr -Mn 0.65 ± 1.01 8.24 ± 2.08 2.42±0.46 0.62 ± 0.10 1.44±0.32 8.56 ± 1.05 0.12 ± 0.02 
+Cr +Hn 1.56±2.62 26.27±7.48 2.07 ± 0.34 0.60 ± 0.08 1.88 ± 1.42 8.18 ± 1. 46 o.u ± o.o1 
1Mean ± SEM 
APPENDIX D 
Group means of mineral concentrations of kidney in obese and 
lean mice fed diets with low and adequate chromium and manganesel, 2 
Cr Mn Fe Zn Ca ·Kg Cu 
umol/g umol/g umol/g urool/g mrool/ g mrool/g umol/g 
Lean 
-Cr -Mn 12.06 ± 5.40 50.90 ± 7.10 4 .so ± 0.67 1.03 ± 0.04 5.60 ± 1.08 14.64 ± 2.45 0.24 ± 0.01 
-Cr +Mn 14.58 ± 15.14 97.63 ± 6.00 5.48 ± 0.31 1.04 ± 0.03 5.20 ± 0.27 16.23 ± 1.04 0.23 ± 0.01 
+Cr -Mn 15.58 ± 2.48 53.90 ± 1.44 4.90±0.19 1.08 ± 0.02 6.07 ± 0.30 15.30 ± 0.52 0.25 ± 0.01 
+Cr +Mn 8.08 ± 2. 72 98.57 ± 8.76 5.25 ± 0.28 1.04 ± 0.02 5.00 ± 0.35 15.79 ±0.93 0.24 ± 0.01 
Obese 
-Cr -Mn 12.17 ± 2.92 45.77 ± 4.-oo 4.86 ± 0.24· 1.01 ± 0.03 6.05 ± 0.37 16.00 ± 1.17 0.11 ± o.oo 
-Cr +Mn 9.21 ± 2.26 85.76 ± 2.35 5.68 ± 0.90 1.00 ± 0.01 5.61 ± 0.25 15.77 ± 0.60 0.26 ± 0.01 
+Cr -Mn 16.65 ± 5.28 46.34 ± 2.00 5.04±0.16 1.03 ± 0.02 5.85 ± 0.33 17.34 ± 0.84 0.27 ± o.oo 
+Cr +Mn 13.30 ± 4.24 91.00 ± 2.68 5.00 ± 0.21 1.00 ± 0.02 5.15 ± 0.21 16.76 ± 0.38 0.11 ,± o.oo 
1Values are mean ± SEM 
APPENDIX E 
Group means of hematological parameters of obese and 
lean mice fed diets with low and adequate chromium and manganestt' 2 
WBC RBC HGB HCT MCV MCH KCBC PLT 
106/L 1012 /L g/Dl X P'l pg g/L 109/L 
Lean 
-Cr -Hn 8.45 ± 1. 77 10.73 ± 0.07 163 ± 2 50.0 ± 1 46.4 ± 0.2 15.2 ± 0.1 328.20 ± 2.40 1252 ± 38 
-Cr +Hn 7.87±1.66 11.22 ± 0.49 170 ± 19 52.0 ± 6 46.4 ± 0.4 15.2 ± 0.1 327.00 ± 6.54 1241 ± 93 
+Cr -Hn 6.17±1.72 10 . 44 ± 0.22 158 ± 9 48.0 ± 3 46.1 ± 0.3 15.1 ± 0.1 328.00 ± 4.52 1276 ± 20 
+Cr +Hn 6.82 ± 2.93 10.73 ± 0.21 162 ± 8 50.0 ± 2 46.1 ± 0.2 15.1 ± 0.2 326.77 ± 6.57 1387 ± 32 
lro Obese 0 
-Cr -Hn 12.26 ± 4.13 10.61 ± 0.13 173 ± 5 51.0 ± 1 48.7±0.1 16.3 ± 0.2 334.ao ±a. 10 1141 ± 37 
-Cr ±Hn 13.93 ± 3.06 11.12 ± 0.20 178 ± 7 54.0 ± 2 48.6 ± 0.3 16.1 ± 0.1 330.40 ± 4.35 1245 ± 30 
+Cr -Hn 12.81 ± 4.14 10.62 ± 0.13 174± 5 52.0 ± 2 48.6 ± 0.1 16.5 ± 0.1 338 . 50 ± 7. 70 1207 ± 25 
+Cr ±Hn 11.64 ± 4 . 46 10 . 74 ± 0.18 175 ± 8 52.0 ± 2 47.5 ± 1.1 16.4 ± 0.1 337.33 ± 6.61 1271 ± 36 
1Mean ± SEM 
APPENDIX F 
Group means of tissue weights of obese and lean 
mice fed diets with low and adequate chromium and manganese1 t 2 
Liver Kidney Spleen Heart Testes Lung Fat3 Thymus 
g g mg g g g g mg 
Lean 
-Cr -Mn 1.03 ± 0.03 0.33 ± 0.01 65.2 ± 2.3 0.13 ± o •. oo 0.21 ± 0.01 0.15 ± 0.01 1.11 ± 0.08 47.1±3.4 
-Cr +Mn 1.06 ± o.os 0.33 ± 0.02 67.1±4.2 0.14 ± 0.01 0.21 ± 0.01 0.21 ± 0.04 0.93 ± 0.10 42.0 ± 4.0 
+Cr -Mn 1.02 ± 0.04 o.31 ± o.o1 59.0 ± 4.2 0.13 ± o.oo 0.21±0.01 0.20 ± 0.01 0.80 ± 0.06 36.1 ± 2.0 
+Cr +Mn 1.06 ± 0.03 0.31 ± 0.01 64.5 ± 3.4 0.13 ± o.oo 0.21 ± 0.01 0.20 ± 0.01 0.92 ± 0.07 42.4 ± 2.8 
Obese 
-Cr -Mn 2.81 ± 0.20 0.32 ± 0.01 60.0 ± 5.0 0.12 ± o.oo 0.18 ± 0.01 0.16 ± 0.01 3.00 ± 0.10 38.7 ± 3.1 
-Cr +Mn 2.60 ± 0.11 0.34 ± 0.02 51.9 ± 2.7 0.13 ± 0.01 0.17 ± 0.14 0.14 ± 0.01 2.88 ± 0.10 44.7 ± 4.5 
+Cr -Mn 2.52 ± 0.15 0.32 ± 0.01 50.3 ± 2.7 0.12 ± o.oo 0.18 ± 0.01 0.13 ± 0.01 3.00 ± 0.11 40.2 ± 4.3 
+Cr +Mn 2.66 ± 0.10 0.32 ± 0.02 51.0 ± 2.5 0.12 ± 0.01 0.16 ± 0.01 0.13 ± 0.01 2.90 ± 0.06 37.4 ± 5.5 
1Mean ± SEM 
3Epididymal fat pad 
APPENDIX G 
Hematological parameters of obese and lean mice fed diets with low and adequate chromium and manganese1 
WBC RBC HGB HCT MCV MCH MCHC PLT 
106/L 1012 /L g/dL % Fl pg g/L 109 /L 
Main Plot: Means 
OB 11.97 ± 0.58 10.78 ± 0.12 176 ± 14 52± 5 48.3 ± 0.2 16.3 ± 0.1 335.2 ± 11.4 1290.2 ± 23.3 
Lean 7.71 ± 0.58 10.76±0.12 163 ± 14 so± 5 46.3 ± 0.2 15.1 ± 0.1 327.5 ± 11.4 1216.0 ± 23.3 
Subplot Means 
-Cr 10.58 ± 0.57 10.92 ± 0.12 171 ± 14 52± 5 47.5 ± 0.2 15.7±0.1 330.1±11.1 1220.0 ± 23.0 
+Cr 9.11 ± 0.58 10.62 ± 0.12 167 ± 14 50± 5 47.1±0.2 15.7±0.1 332.6 ± 11.6 1287 .o ± 23.7 
-Mn 9.64 ± 0.57 10.60±0.12 167 ± 14 50± 5 47.5±0.2 15 •. 8±0.1 332.3 ± 11.2 1219 .• 0 ± 23.0 
+Mn 10.05 ± 0.60 11.00 ± 0.12 171 ± 14 52± 5 47.2±0.2 15.6 ± 0.1 330.4 ± 11.6 1287.3 ± 24.0 
Source of Variation 
Gene < 0.0001 0.94 < 0.0001 < 0.0025 < 0.0001 < 0.0001 < 0.0001 < 0.02 
Cr 0.08 0.08 0.07 < 0.03 0.14 0.50 0.11 < o.os 
Mn 0.62 < 0.04 0.04 < 0.03 0.33 0.26 0.23 < 0.04 
Gene x Cr 0.36 0.45 0.07 0.34 0.60 0.11 0.10 0.52 
Gene x Mn 0.86 0.90 0.72 0.86 0.26 0.54 . 0.62 0.63 
CrxMn 0.91 0.35 0.40 0.36 0.50 0.56 . 0.61 0.52 
Gene x Cr x Hn 0.52 0.86 0.93 0.84 0.37 0.68 0.62 0.21 
1Values are least squares means± SEM (Gene, N = 39-40, Cr, N = 39-40, Mn, N = 39-40) 
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